Outlook Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Net Income	-102.86	-62.42	-75.37	-58.98	-66.05	-53.16
Depreciation & Amortization	0.12	0.12	0.11	0.04	0.2	0.26
Stock-Based Compensation	6.11	8.9	5.39	5.55	7.71	4.89
Other Adjustments	30.48	39.74	42.73	5.66	3.15	0.84
Change in Receivables	1.38	-1.49	-	-	-	-
Changes in Inventories	-0.35	-3.34	-	-	-	-
Changes in Accounts Payable	-1.04	1.67	1.39	3.08	1.3	-0.2
Changes in Accrued Expenses	1.48	1.71	0.49	-0.71	0.16	-5.3
Changes in Income Taxes Payable	-	-1.55	-	-	-	-
Changes in Other Operating Activities	2.66	7.87	-4.9	2.38	-3.14	-1.58
Operating Cash Flow	-55.8	-51.83	-68.79	-42.97	-56.67	-54.25
Long-Term Debt Issued	16.55	33.1	-	30	10	10
Long-Term Debt Repaid	-19.69	-36.14	-	-10.22	-12.29	-3.66
Net Long-Term Debt Issued (Repaid)	-3.14	-3.04	-	19.78	-2.29	6.34
Issuance of Common Stock	64.72	48.03	60.33	30.02	62.51	49.9
Net Common Stock Issued (Repurchased)	64.72	48.03	60.33	30.02	62.51	49.9
Other Financing Activities	-	-	-0	-0.84	-0.63	-0.04
Financing Cash Flow	58.78	44.98	60.33	48.97	59.59	56.19
Net Cash Flow	2.97	-6.84	-8.46	6	2.92	1.94
Free Cash Flow	-55.8	-51.83	-68.79	-42.97	-56.67	-54.25
FCF Margin	-27127.21%	-3666.65%	-	-	-	-
Free Cash Flow Per Share	-1.27	-1.49	-3.71	-3.44	-5.34	-7.11
Levered Free Cash Flow	-103.12	-59	-78.27	-34.41	-69.82	-53.64
Unlevered Free Cash Flow	-54.94	-58.97	-74.61	-48.33	-64.55	-58.55

Updated Feb 17, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q